Delcath Systems (DCTH) Competitors

Delcath Systems (NASDAQ:DCTH) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Does the media refer more to DCTH or BWAY?

In the previous week, BrainsWay had 4 more articles in the media than Delcath Systems. MarketBeat recorded 23 mentions for BrainsWay and 19 mentions for Delcath Systems. BrainsWay's average media sentiment score of 0.89 beat Delcath Systems' score of 0.61 indicating that BrainsWay is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BrainsWay	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of DCTH or BWAY?

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts recommend DCTH or BWAY?

Delcath Systems currently has a consensus price target of $21.50, indicating a potential upside of 128.97%. BrainsWay has a consensus price target of $13.17, indicating a potential upside of 44.37%. Given Delcath Systems' higher possible upside, equities research analysts clearly believe Delcath Systems is more favorable than BrainsWay.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
BrainsWay	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is DCTH or BWAY more profitable?

BrainsWay has a net margin of 3.88% compared to Delcath Systems' net margin of -150.70%. BrainsWay's return on equity of 3.52% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	-150.70%	-338.16%	-104.02%
BrainsWay	3.88%	3.52%	2.26%

Does the MarketBeat Community prefer DCTH or BWAY?

BrainsWay received 38 more outperform votes than Delcath Systems when rated by MarketBeat users. Likewise, 66.67% of users gave BrainsWay an outperform vote while only 25.64% of users gave Delcath Systems an outperform vote.

Company	Underperform	Outperform
Delcath Systems	Outperform Votes 30 25.64%	Underperform Votes 87 74.36%
BrainsWay	Outperform Votes 68 66.67%	Underperform Votes 34 33.33%

Which has more risk & volatility, DCTH or BWAY?

Delcath Systems has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Which has stronger valuation & earnings, DCTH or BWAY?

BrainsWay has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$2.07M	145.02	-$47.68M	-$1.35	-6.96
BrainsWay	$31.78M	4.79	-$4.20M	$0.10	91.21

Summary

BrainsWay beats Delcath Systems on 13 of the 17 factors compared between the two stocks.